NCT02546323 - A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis | Biotech Hunter

Enrollment

543

Participants

Timeline

Start Date

September 17, 2015

Primary Completion Date

January 29, 2019

Study Completion Date

January 29, 2019

Conditions

Atherosclerosis

Interventions

DRUG

Rosuvastatin

20mg tablets, orally once daily for the duration of the 104-week treatment period

DRUG

Placebo

Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.

Trial Locations (24)

100035

Research Site, Beijing

100050

Research Site, Beijing

100191

Research Site, Beijing

100853

Research Site, Beijing

110001

Research Site, Shenyang

150001

Research Site, Haerbin

200032

Research Site, Shanghai

200065

Research Site, Shanghai

200090

Research Site, Shanghai

210009

Research Site, Nanjing

233060

Research Site, Bengbu

300457

Research Site, Tianjin

315010

Research Site, Ningbo

330006

Research Site, Nanchang

400042

Research Site, Chongqin

410011

Research Site, Changsha

430022

Research Site, Wuhan

510080

Research Site, Guangzhou

510120

Research Site, Guangzhou

510260

Research Site, Guangzhou

510515

Research Site, Guangzhou

510630

Research Site, Guangzhou

710061

Research Site, Xi'an

CN-325000

Research Site, Wenzhou